HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 7 (July)

1. Granuloma and cryptococcosis.
   J Infect Chemother, 11(3): 115-22. [Abstract] [Full-text]
2. Characterization of a long terminal repeat region from an infectious Indian HIV type 2 isolate.
   AIDS Res Hum Retroviruses, 21(6): 592-6. [Abstract] [Full-text]
3. Enfuvirtide is active against HIV type 1 group O.
   AIDS Res Hum Retroviruses, 21(6): 583-5. [Abstract] [Full-text]
4. Full-length HIV type 1 genome analysis showing evidence for HIV type 1 transmission from a nonprogressor to two recipients who progressed to AIDS.
   AIDS Res Hum Retroviruses, 21(6): 575-9. [Abstract] [Full-text]
5. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation.
   AIDS Res Hum Retroviruses, 21(6): 565-74. [Abstract] [Full-text]
6. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau.
   AIDS Res Hum Retroviruses, 21(6): 560-4. [Abstract] [Full-text]
7. Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.
   AIDS Res Hum Retroviruses, 21(6): 545-54. [Abstract] [Full-text]
8. Temporal trends in HIV Type 1 incidence among inner-city childbearing women in Atlanta: use of the IgG-capture BED-enzyme immunoassay.
   AIDS Res Hum Retroviruses, 21(6): 537-44. [Abstract] [Full-text]
9. Human herpesvirus-8 seropositivity and clinical correlations in HIV-1-positive and highly exposed, persistently HIV-seronegative individuals in Greece.
   AIDS Patient Care STDS, 19(6): 375-83. [Abstract] [Full-text]
10. Induction of 15-lipoxygenase-1 impairs expression of HIV-1 receptors CD4 and CXCR4 in monocytic cells.
    FEBS Lett, 579(17): 3691-4. [Abstract] [Full-text]
11. Subtype C Is associated with increased vaginal shedding of HIV-1.
    J Infect Dis, 192(3): 492-6. [Abstract] [Full-text]
12. Investigation of HIV in amniotic fluid from HIV-infected pregnant women at full term.
    J Infect Dis, 192(3): 488-91. [Abstract] [Full-text]
13. Molecular diversity of HIV in Albania.
    J Infect Dis, 192(3): 475-9. [Abstract] [Full-text]
14. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
    J Infect Dis, 192(3): 466-74. [Abstract] [Full-text]
15. Immunological response to highly active antiretroviral therapy in children with clinically stable HIV-1 infection.
    J Infect Dis, 192(3): 445-55. [Abstract] [Full-text]
16. Intrapatient escape in the A*0201-restricted epitope SLYNTVATL drives evolution of human immunodeficiency virus type 1 at the population level.
    J Virol, 79(14): 9363-6. [Abstract] [Full-text]
17. Reduced mobilization of Rev-responsive element-deficient lentiviral vectors.
    J Virol, 79(14): 9359-62. [Abstract] [Full-text]
18. Comparison of the genetic recombination rates of human immunodeficiency virus type 1 in macrophages and T cells.
    J Virol, 79(14): 9337-40. [Abstract] [Full-text]
19. In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.
    J Virol, 79(14): 9197-205. [Abstract] [Full-text]
20. Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.
    J Virol, 79(14): 9180-91. [Abstract] [Full-text]
21. Analysis of human immunodeficiency virus type 1 Gag ubiquitination.
    J Virol, 79(14): 9134-44. [Abstract] [Full-text]
22. Defective replication in human immunodeficiency virus type 1 when non-primers are used for reverse transcription.
    J Virol, 79(14): 9081-7. [Abstract] [Full-text]
23. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
    J Virol, 79(14): 9069-80. [Abstract] [Full-text]
24. Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1.
    J Virol, 79(14): 9038-45. [Abstract] [Full-text]
25. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.
    J Virol, 79(14): 9026-37. [Abstract] [Full-text]
26. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.
    J Virol, 79(14): 9006-18. [Abstract] [Full-text]
27. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.
    J Virol, 79(14): 8979-90. [Abstract] [Full-text]
28. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses.
    J Virol, 79(14): 8878-85. [Abstract] [Full-text]
29. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells.
    J Virol, 79(14): 8861-9. [Abstract] [Full-text]
30. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.
    J Virol, 79(14): 8828-34. [Abstract] [Full-text]
31. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
    J Virol, 79(14): 8812-27. [Abstract] [Full-text]
32. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
    J Virol, 79(14): 8724-31. [Abstract] [Full-text]
33. Sex work, drug use, HIV infection, and spread of sexually transmitted infections in Moscow, Russian Federation.
    Lancet, 366(9479): 57-60. [Abstract] [Full-text]
34. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus.
    Virus Res, 111(2): 194-213. [Abstract] [Full-text]
35. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication.
    J Biol Chem, 280(27): 25517-23. [Abstract] [Full-text]
36. Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects.
    J Leukoc Biol, 78(1): 37-42. [Abstract] [Full-text]
37. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.
    Blood, 106(2): 572-6. [Abstract] [Full-text]
38. Oligoclonal T cells are infiltrating the brains of children with AIDS: sequence analysis reveals high proportions of identical beta-chain T-cell receptor transcripts.
    Clin Exp Immunol, 141(2): 338-56. [Abstract] [Full-text]
39. The impact of HIV/AIDS on the control of tuberculosis in India.
    Proc Natl Acad Sci U S A, 102(27): 9619-24. [Abstract] [Full-text]
40. Macrophages archive HIV-1 virions for dissemination in trans.
    EMBO J, 24(13): 2481-9. [Abstract] [Full-text]
41. Evaluation of rapid prenatal human immunodeficiency virus testing in rural cameroon.
    Clin Diagn Lab Immunol, 12(7): 855-60. [Abstract] [Full-text]
42. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
    Bioorg Med Chem Lett, 15(15): 3496-500. [Abstract] [Full-text]
43. Anti-HIV properties of cationic fullerene derivatives.
    Bioorg Med Chem Lett, 15(15): 3615-8. [Abstract] [Full-text]
44. Serostatus disclosure, seroconcordance, partner relationship, and unprotected anal intercourse among HIV-positive Latino men who have sex with men.
    AIDS Educ Prev, 17(3): 227-37. [Abstract] [Full-text]
45. Need fulfillment in the sexual relationships of HIV-infected men who have sex with men.
    AIDS Educ Prev, 17(3): 217-26. [Abstract] [Full-text]
46. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).
    Vaccine, 23(34): 4292-301. [Abstract] [Full-text]
47. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Arch Intern Med, 165(13): 1533-40. [Abstract] [Full-text]
48. Posterior reversible encephalopathic syndrome due to severe hypercalcemia in AIDS.
    Scand J Infect Dis, 37(6): 524-6. [Abstract] [Full-text]
49. Exploratory Bayesian model selection for serial genetics data.
    Biometrics, 61(2): 591-9. [Abstract] [Full-text]
50. High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control.
    J Virol, 79(15): 10059-62. [Abstract] [Full-text]
51. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells.
    J Virol, 79(15): 10053-8. [Abstract] [Full-text]
52. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis.
    J Virol, 79(15): 9954-69. [Abstract] [Full-text]
53. Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta.
    J Virol, 79(15): 9821-30. [Abstract] [Full-text]
54. Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status.
    J Virol, 79(15): 9799-809. [Abstract] [Full-text]
55. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.
    J Virol, 79(15): 9625-34. [Abstract] [Full-text]
56. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes.
    J Virol, 79(15): 9618-24. [Abstract] [Full-text]
57. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    J Virol, 79(15): 9579-87. [Abstract] [Full-text]
58. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    J Virol, 79(15): 9572-8. [Abstract] [Full-text]
59. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction.
    J Virol, 79(15): 9410-8. [Abstract] [Full-text]
60. Human and nonhuman primate lentiviral infection and autoimmunity.
    Ann N Y Acad Sci, 1050: 397-409. [Abstract] [Full-text]
61. Clue to fine-needle aspiration diagnosis of pleural pneumocystoma: neovascularization and Langhans' giant cell reaction.
    Diagn Cytopathol, 33(2): 97-9. [Abstract] [Full-text]
62. Primary hepatic anaplastic large-cell lymphoma diagnosed by fine-needle aspiration biopsy.
    Diagn Cytopathol, 33(2): 106-9. [Abstract] [Full-text]
63. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors.
    Proc Natl Acad Sci U S A, 102(28): 9860-5. [Abstract] [Full-text]
64. Seven years of HAART impact on ophthalmic management of HIV-infected patients.
    Ocul Immunol Inflamm, 13(2): 213-8. [Abstract] [Full-text]
65. Dr. Wouter Basson, Americans, and wild beasts: men's conspiracy theories of HIV/AIDS in the South African Lowveld.
    Med Anthropol, 24(2): 179-208. [Abstract] [Full-text]
66. Plasma cell tumors in HIV-positive patients: report of a case and review of the literature.
    Leuk Lymphoma, 46(7): 1067-74. [Abstract] [Full-text]
67. The aging HIV/AIDS population: fragile social networks.
    Aging Ment Health, 9(3): 246-54. [Abstract] [Full-text]
68. Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in Greece.
    Virus Res, 112(1): 115-22. [Abstract] [Full-text]
69. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Vaccine, 23(36): 4463-72. [Abstract] [Full-text]
70. A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer.
    J Virol Methods, 128(1): 93-103. [Abstract] [Full-text]
71. Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase.
    J Virol Methods, 128(1): 135-42. [Abstract] [Full-text]
72. Viral infectivity is maintained by an RNA protection buffer.
    J Virol Methods, 128(1): 189-91. [Abstract] [Full-text]
73. Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection.
    J Virol Methods, 128(1): 128-34. [Abstract] [Full-text]
74. Optimization of a genotypic assay applicable to all human immunodeficiency virus type 1 protease and reverse transcriptase subtypes.
    J Virol Methods, 128(1): 47-53. [Abstract] [Full-text]
75. Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin.
    J Infect Dis, 192(4): 630-9. [Abstract] [Full-text]
76. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
    J Infect Dis, 192(4): 607-17. [Abstract] [Full-text]
77. Alanine scanning mutants of the HIV gp41 loop.
    J Biol Chem, 280(29): 27284-8. [Abstract] [Full-text]
78. HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses.
    EMBO J, 24(14): 2634-45. [Abstract] [Full-text]
79. Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.
    Drugs Today (Barc), 41(4): 241-52. [Abstract] [Full-text]
80. Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.
    J Gen Virol, 86: 2221-9. [Abstract] [Full-text]
81. Conjunctival squamous cell carcinoma: atypical presentation of HIV.
    Clin Experiment Ophthalmol, 33(4): 419-20. [Abstract] [Full-text]
82. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.
    Blood, 106(3): 818-26. [Abstract] [Full-text]
83. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells.
    J Neurovirol, 11(3): 281-91. [Abstract] [Full-text]
84. Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy.
    J Neurovirol, 11(2): 219-24. [Abstract] [Full-text]
85. Human immunodeficiency virus type 1 genetic diversity in the nervous system: evolutionary epiphenomenon or disease determinant?
    J Neurovirol, 11(2): 107-28. [Abstract] [Full-text]
86. The effectiveness of media use in health education: evaluation of an HIV/AIDS television campaign in Ethiopia.
    J Health Commun, 10(3): 225-35. [Abstract] [Full-text]
87. Plasma cytokines and oxidative damage in HIV-positive and HIV-negative adolescents and young adults: a protective role for IL-10?
    Free Radic Res, 39(8): 859-64. [Abstract] [Full-text]
88. Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics--a mini review.
    Eur J Contracept Reprod Health Care, 10(1): 32-42. [Abstract] [Full-text]
89. Barriers to HIV/AIDS knowledge and prevention among deaf and hard of hearing people.
    AIDS Care, 17(5): 623-34. [Abstract] [Full-text]
90. Barriers to accessing HIV/AIDS care in North Carolina: rural and urban differences.
    AIDS Care, 17(5): 558-65. [Abstract] [Full-text]
91. AIDS-related discrimination in Asia.
    AIDS Care, 17(4): 413-24. [Abstract] [Full-text]
92. HIV-1 superinfection is not a common event.
    J Clin Virol, 33(4): 328-30. [Abstract] [Full-text]
93. Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir.
    J Clin Virol, 33(4): 319-23. [Abstract] [Full-text]
94. High levels of discordance between sequencing and serological subtyping in a predominantly non-B subtype HIV-1 infected cohort.
    J Clin Virol, 33(4): 312-8. [Abstract] [Full-text]
95. N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies.
    Viral Immunol, 18(2): 343-53. [Abstract] [Full-text]
96. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.
    Viral Immunol, 18(2): 317-26. [Abstract] [Full-text]
97. Poly(ADP-ribose)polymerase-1 is required for integration of the human immunodeficiency virus type 1 genome near centromeric alphoid DNA in human and murine cells.
    Biochem Biophys Res Commun, 334(2): 412-7. [Abstract] [Full-text]
98. The management of HIV-1 protease inhibitor pharmacokinetic interactions.
    J Antimicrob Chemother, 56(1): 1-5. [Abstract] [Full-text]
99. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.
    J Antimicrob Chemother, 56(1): 190-5. [Abstract] [Full-text]
100. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol.
     J Antimicrob Chemother, 56(1): 186-9. [Abstract] [Full-text]
101. The AIDS epidemic in the city of Copenhagen, Denmark: potential years of life lost and impact on life expectancy.
     Scand J Public Health, 33(3): 222-7. [Abstract] [Full-text]
102. Genetic analysis of human immunodeficiency virus type 1 nef in Portugal: subtyping, identification of mosaic genes, and amino acid sequence variability.
     J Med Virol, 77(1): 8-16. [Abstract] [Full-text]
103. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
     J Med Virol, 77(1): 23-8. [Abstract] [Full-text]
104. Detection of human immunodeficiency virus type 1 RNA by in situ hybridization in oral mucosa epithelial cells from anti-HIV-1 positive patients.
     J Med Virol, 77(1): 17-22. [Abstract] [Full-text]
105. Conformational pathway for the kissing complex-->extended dimer transition of the SL1 stem-loop from genomic HIV-1 RNA as monitored by targeted molecular dynamics techniques.
     J Mol Biol, 351(3): 520-30. [Abstract] [Full-text]
106. 2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy.
     Clin Exp Immunol, 141(3): 526-33. [Abstract] [Full-text]
107. CDC staging based on absolute CD4 count and CD4 percentage in an HIV-1-infected Indian population: treatment implications.
     Clin Exp Immunol, 141(3): 485-90. [Abstract] [Full-text]
108. No evidence of prolonged enterovirus excretion in HIV-seropositive patients.
     Trop Med Int Health, 10(8): 743-7. [Abstract] [Full-text]
109. Intimate partner violence, substance use, and HIV among low-income women: taking a closer look.
     Violence Against Women, 11(9): 1140-61. [Abstract] [Full-text]
110. TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.
     Antimicrob Agents Chemother, 49(8): 3483-5. [Abstract] [Full-text]
111. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
     Antimicrob Agents Chemother, 49(8): 3474-82. [Abstract] [Full-text]
112. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
     Antimicrob Agents Chemother, 49(8): 3361-6. [Abstract] [Full-text]
113. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
     Antimicrob Agents Chemother, 49(8): 3355-60. [Abstract] [Full-text]
114. Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1.
     Antimicrob Agents Chemother, 49(8): 3334-40. [Abstract] [Full-text]
115. Influence of depression and HIV serostatus on the neuropsychological performance of injecting drug users.
     Psychiatry Clin Neurosci, 59(4): 372-8. [Abstract] [Full-text]
116. Anti-HIV-1 activities in extracts from some medicinal plants as assessed in an in vitro biochemical HIV-1 reverse transcriptase assay.
     Phytother Res, 19(4): 287-90. [Abstract] [Full-text]
117. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia.
     J Virol, 79(16): 10830-4. [Abstract] [Full-text]
118. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
     J Virol, 79(16): 10718-29. [Abstract] [Full-text]
119. Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype.
     J Virol, 79(16): 10701-8. [Abstract] [Full-text]
120. Nef proteins from diverse groups of primate lentiviruses downmodulate CXCR4 to inhibit migration to the chemokine stromal derived factor 1.
     J Virol, 79(16): 10650-9. [Abstract] [Full-text]
121. Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.
     J Virol, 79(16): 10638-49. [Abstract] [Full-text]
122. Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations.
     J Virol, 79(16): 10627-37. [Abstract] [Full-text]
123. Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease.
     J Virol, 79(16): 10601-7. [Abstract] [Full-text]
124. Primary sooty mangabey simian immunodeficiency virus and human immunodeficiency virus type 2 nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication.
     J Virol, 79(16): 10547-60. [Abstract] [Full-text]
125. An exonic splicing silencer downstream of the 3' splice site A2 is required for efficient human immunodeficiency virus type 1 replication.
     J Virol, 79(16): 10478-86. [Abstract] [Full-text]
126. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase.
     J Virol, 79(16): 10356-68. [Abstract] [Full-text]
127. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
     J Virol, 79(16): 10237-46. [Abstract] [Full-text]
128. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 env can be used to induce high-titer neutralizing antibody responses.
     J Virol, 79(16): 10210-7. [Abstract] [Full-text]
129. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
     J Virol, 79(16): 10108-25. [Abstract] [Full-text]
130. Demographics in HIV-infected children in Denmark: results from the Danish Paediatric HIV Cohort Study.
     Scand J Infect Dis, 37(5): 344-9. [Abstract] [Full-text]
131. Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study.
     Scand J Infect Dis, 37(5): 338-43. [Abstract] [Full-text]
132. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity.
     Cell, 122(2): 169-82. [Abstract] [Full-text]
133. And the noise played on: stochastic gene expression and HIV-1 infection.
     Cell, 122(2): 147-9. [Abstract] [Full-text]
134. The mucosal immune system: from control of inflammation to protection against infections.
     J Leukoc Biol, 78(2): 311-8. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.